Inhibrx Biosciences (INBX) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Novavax (NVAX) has outperformed Inhibrx Biosciences (INBX) over the past year, gaining 15.5% versus a loss of 17.8%. Novavax is the larger company by market cap ($1.23 billion vs $1.02 billion), about 1.2 times the size, while Inhibrx Biosciences is growing revenue faster (+550.0% vs +64.7%). Novavax converts more of its revenue into profit, with a net margin of 39.2% versus -10773.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | NVAX |
|---|---|---|
| Share price | $68.97 | $7.47 |
| Market cap | $1.02B | $1.23B |
| 1-day change | -7.21% | -3.24% |
| YTD return | -12.70% | +11.16% |
| 1-year return | -17.82% | +15.46% |
| 5-year return | — | -96.57% |
| EPS (TTM) | $-9.06 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.30M | $1.12B |
| Revenue growth (YoY) | +550.00% | +64.69% |
| Net income (latest FY) | $-140.06M | $440.30M |
| Gross margin | — | 93.50% |
| Operating margin | -10386.54% | 40.30% |
| Net margin | -10773.46% | 39.19% |
| 52-week high | $155.29 | $13.39 |
| 52-week low | $57.30 | $6.36 |
| Distance from 52-week high | -55.59% | -44.21% |
| Analyst consensus | none | buy |
| Avg. price target upside | +286.65% | +88.89% |
| Average volume | 305.96K | 6.67M |
| Shares outstanding | 14.77M | 165.01M |
| Employees | 109 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed INBX by 33.3 percentage points over the past year.
- Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus -10773.5 cents for Inhibrx Biosciences.
- Inhibrx Biosciences grew revenue faster in its latest fiscal year (+550.00% vs +64.69%).
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
INBX vs NVAX FAQ
Which is bigger, Inhibrx Biosciences or Novavax?
Novavax (NVAX) is larger, with a market capitalization of $1.23B compared with $1.02B for Inhibrx Biosciences (INBX).
Which stock has performed better over the past year, INBX or NVAX?
NVAX returned +15.46% over the past 12 months, compared with -17.82% for INBX (price return, excluding dividends). Past performance does not predict future results.
Are Inhibrx Biosciences and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.